GHK-Cu (Copper Tripeptide-1)

What it is

GHK is a three-amino-acid peptide—glycine, histidine, lysine—that occurs naturally in human plasma. Bind it to a copper ion and you get GHK-Cu. Loren Pickart first isolated it in 1973, and much of the foundational research still comes from Pickart and colleagues. (Pickart & Margolina, 2018, IJMS)

The "restore your youthful levels" pitch leans on one repeated figure: plasma GHK is "about 200 ng/mL" at age 20 and "declines to 80 ng/mL" by age 60. The seam matters. That number traces to Pickart's own reviews, not an independent large-population study. (Pickart & Margolina, 2018 — verbatim source of the figure)

In cells, GHK-Cu carries copper and affects collagen synthesis, certain matrix enzymes, and a large swath of gene expression. Route is not a footnote here. A topical cosmetic record cannot be pasted onto an injected product.

What humans actually show

Path A — Topical / cosmetic (the version with actual human data):

• A randomized study of 13 people using GHK-Cu skin care after CO2 laser resurfacing found no objective improvement in redness, wrinkles, or overall skin quality versus the comparison regimen. Patient satisfaction was higher. (Miller et al., 2006)
• A 12-week facial-cream study in 71 women with photoaging reported denser, thicker skin, less laxity, and shallower fine lines and wrinkles. (Pickart & Margolina, 2018)
• Now the seam: the key cosmetic studies from Leyden, Finkey and colleagues were largely conference presentations and industry-sponsored work, not peer-reviewed randomized trials. The famous "67% wrinkle reduction" and the N=71 figure trace to an industry-sponsored poster at the American Academy of Dermatology's 60th Annual Meeting in New Orleans in February 2002. It is not a PubMed-indexed paper, and the percentage could not be checked against a primary abstract or dataset. The topical signal may be real. The marketing-grade precision is not independently verifiable.

Path B — Injected / systemic (the version with no human data):

• PepCurrent's August 2 source search found no human trial that administered GHK-Cu by injection or another systemic route. The PubMed-indexed clinical trial used topical skin care after laser resurfacing. ClinicalTrials.gov records a topical GHK-Cu wound gel and a non-drug patch study measuring circulating GHK/GHK-Cu levels—not an injected GHK-Cu intervention. Claims about injected GHK-Cu for injury healing or longevity therefore remain supported only by cell-culture and animal evidence, not an administered human trial. (Miller et al., 2006 — topical clinical trial; ClinicalTrials.gov — topical GHK-Cu gel, NCT07437586; ClinicalTrials.gov — X39 patch study, NCT07706361)

The "resets 4,000 genes" claim: Yes, GHK changed gene activity—in a database of cultured cells. The 2014 analysis reported changes greater than 50% in 32.1% of the genes tested, roughly 4,000+ of 13,424. That is a cell-culture expression signature, not a younger human body. (Pickart et al., 2014, BioMed Research International)

FDA and U.S. status

• Topical/cosmetic: GHK-Cu ("Copper Tripeptide-1") is a legal, widely sold cosmetic ingredient, regulated as a cosmetic (not a drug). This status is unchanged by the 2026 peptide actions.
• Injectable/compounded: FDA's compounding-safety page lists GHK-Cu for injectable routes among nominations withdrawn by nominators. FDA separately announced that a Pharmacy Compounding Advisory Committee meeting before the end of February 2027 will discuss GHK-Cu for possible inclusion on the 503A Bulks List. The exact date, time, location, and materials remain pending, and advisory recommendations are non-binding. The announcement is not a vote, recommendation, final list action, drug approval, ban, or product-authentication finding. (FDA compounding-safety page; FDA PCAC meeting announcement)
• WADA / sport: Not on the 2026 Prohibited List.

The current FDA pages establish the withdrawn-nomination record and the announced advisory process. PepCurrent does not convert either into a final FDA list action or approval conclusion.

Risks and warning limits

• Topical: Decades of cosmetic use have not produced a notable adverse-event signal, but there is no large formal safety-trial dataset.
• Injected/systemic: There is no long-term human safety dataset because PepCurrent found no administered injected or systemic human trial. Copper overload is a theoretical concern with repeated systemic exposure; the reviewed record does not quantify it for GHK-Cu.
• The category error: A cosmetic-ingredient safety record does not validate injection. Same name, different route, missing evidence.

What people are hearing

• Topical: Serums and creams (INCI "Copper Tripeptide-1"), often marketed for firmness, fine lines, and post-procedure recovery.
• Injected (gray market): Online communities promote it for "healing" and "anti-aging." PepCurrent found no human trial supporting those injected uses.
• Common misconceptions: "Resets 4,000 genes to make you younger" (a cell-culture expression signature, not human rejuvenation); "injecting it heals injuries / extends life" (zero human trials); "regrows hair" (no controlled human hair-regrowth trial in the verified literature).
• Product reality: Topical cosmetics and injectable research or compounded material may share an ingredient name without sharing an evidence record.

What would change this answer

• The announced FDA advisory meeting before the end of February 2027: exact date, materials, voting questions, any committee recommendation, and any later final FDA action.
• Any actual human trial of systemic GHK-Cu — the single thing that would change the injected story.
• Cosmetic-vs-drug line — whether marketing of injectables triggers FDA enforcement.

Sources and records

• Pickart & Margolina, 2018 — Regenerative and Protective Actions of the GHK-Cu Peptide (IJMS)
• Pickart et al., 2014 — GHK and DNA: Resetting the Human Genome to Health (the gene-expression source)
• Miller et al., 2006 — topical GHK-Cu after CO2 laser resurfacing
• ClinicalTrials.gov — topical GHK-Cu wound gel, NCT07437586
• ClinicalTrials.gov — X39 patch study measuring circulating GHK/GHK-Cu, NCT07706361
• FDA compounding substances that may present significant safety risks
• FDA announcement for the planned Pharmacy Compounding Advisory Committee meeting

We do not link to vendors, telehealth prescribers, or supplement sellers.